iTeos Therapeutics, Inc. - Common Stock (ITOS)
5.1800
-0.2100 (-3.90%)
NASDAQ · Last Trade: Apr 10th, 11:13 AM EDT
Via Benzinga · April 3, 2025

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments that defied the trend by moving lower.
Via Talk Markets · September 22, 2024

Via Benzinga · September 17, 2024

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.
Via Investor's Business Daily · September 16, 2024

Via Benzinga · September 16, 2024

Via Benzinga · September 16, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 10, 2024

Via Benzinga · May 10, 2024

Via Benzinga · May 10, 2024

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via Benzinga · October 17, 2023

U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · October 17, 2023

Although U.S. stocks closed lower on Thursday following the CPI data, there were a few notable insider trades.
Via Benzinga · October 13, 2023

Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for PD-L1-high
Via Benzinga · August 23, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Wednesday. The Dow traded up 0.51% to 34,462.61 while the NASDAQ rose 1.60% to 13,722.24. The S&P 500, also rose, gaining, 1.08% to 4,435.09.
Via Benzinga · August 23, 2023

Via Benzinga · August 23, 2023

Stocks are firmly higher this afternoon, despite Foot Locker dragging the athletic segment of the retail sector with its dismal forecast.
Via Talk Markets · August 23, 2023

Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.
Via Benzinga · August 23, 2023

ITeos Therapeutics, Inc. (NASDAQ: ITOS) shares are trading higher Wednesday after the release of Roche's non-small cell lung cancer (NSCLC
Via Benzinga · August 23, 2023